Published in Eur Urol on January 26, 2010
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One (2011) 1.35
Application of metabolomics to prostate cancer. Urol Oncol (2011) 1.28
Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS (2011) 1.23
The role of sarcosine metabolism in prostate cancer progression. Neoplasia (2013) 1.18
Toward the detection of prostate cancer in urine: a critical analysis. J Urol (2012) 1.13
Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry. Br J Cancer (2011) 1.08
Metabolomics in drug target discovery. Cold Spring Harb Symp Quant Biol (2011) 1.05
Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prev (2013) 1.03
Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One (2011) 1.03
Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00
Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol (2010) 0.99
Sarcosine as a potential prostate cancer biomarker--a review. Int J Mol Sci (2013) 0.99
Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis (2013) 0.96
Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery. PLoS One (2013) 0.94
Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J Urol (2011) 0.88
Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep (2011) 0.88
Cavitand-functionalized SWCNTs for N-methylammonium detection. J Am Chem Soc (2012) 0.87
The present and future of prostate cancer urine biomarkers. Int J Mol Sci (2013) 0.85
Identification of aberrant pathways and network activities from high-throughput data. Brief Bioinform (2012) 0.85
Applications of metabolomics in cancer research. J Carcinog (2013) 0.85
Genetic polymorphisms of the glycine N-methyltransferase and prostate cancer risk in the health professionals follow-up study. PLoS One (2014) 0.84
Metabolomic profiling of hormone-dependent cancers: a bird's eye view. Trends Endocrinol Metab (2015) 0.83
Current early diagnostic biomarkers of prostate cancer. Asian J Androl (2014) 0.81
A case control study of sarcosine as an early prostate cancer detection biomarker. BMC Urol (2015) 0.79
Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Urine markers and prostate cancer. Cent European J Urol (2011) 0.78
Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies. Transl Oncol (2016) 0.78
Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol (2016) 0.78
Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study. Int J Med Sci (2017) 0.77
Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS One (2015) 0.77
Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer. Curr Metabolomics (2014) 0.77
Biomarker Discovery and Translation in Metabolomics. Curr Metabolomics (2016) 0.77
Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification of Prostate Cancer. Sci Rep (2016) 0.76
Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer. Front Endocrinol (Lausanne) (2012) 0.76
The Role of Sarcosine, Uracil, and Kynurenic Acid Metabolism in Urine for Diagnosis and Progression Monitoring of Prostate Cancer. Metabolites (2017) 0.75
Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes. Sci Rep (2016) 0.75
Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics. Sci Rep (2016) 0.75
Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). EJIFCC (2014) 0.75
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. EBioMedicine (2017) 0.75
Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer. PLoS One (2016) 0.75
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. J Biomark (2014) 0.75
Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics (2017) 0.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol (2009) 5.62
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology (2009) 4.11
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother (2009) 2.86
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol (2009) 2.60
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol (2007) 2.50
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol (2010) 2.48
Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res (2007) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol (2008) 2.29
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol (2006) 2.21
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem (2002) 2.17
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med (Berl) (2005) 2.16
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol (2012) 2.10
Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU Int (2013) 2.10
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res (2008) 2.06
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol (2003) 2.04
Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem (2010) 1.99
Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol (2005) 1.97
Comparison of eight computer programs for receiver-operating characteristic analysis. Clin Chem (2003) 1.96
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol (2005) 1.93
In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol (2007) 1.93
Development and external validation of an extended 10-core biopsy nomogram. Eur Urol (2006) 1.90
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem (2006) 1.88
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol (2007) 1.83
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol (2010) 1.82
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int (2009) 1.80
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol (2008) 1.78
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. Eur Urol (2006) 1.71
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol (2008) 1.71
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 1.68
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Pathology of peliosis. Forensic Sci Int (2005) 1.68
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
Impact of RNA degradation on gene expression profiling. BMC Med Genomics (2010) 1.67
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer (2004) 1.66
ERG rearrangement in small cell prostatic and lung cancer. Histopathology (2010) 1.64
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol (2006) 1.63
Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol (2007) 1.62
A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. Eur Urol (2007) 1.62
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem (2011) 1.59
Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol (2013) 1.59
Molecular cancer phenotype in normal prostate tissue. Eur Urol (2008) 1.58